We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00794014
First Posted: November 19, 2008
Last Update Posted: February 13, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hyeon-Cheol Gwon, Samsung Medical Center
  Purpose
The purpose of this study is to establish the optimal strategy for side branch stenting in coronary bifurcation lesion.

Condition Intervention
Coronary Artery Disease Procedure: Conservative strategy Procedure: Aggressive strategy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Optimal Strategy for Side Branch Stenting in Coronary Bifurcation Lesion

Further study details as provided by Hyeon-Cheol Gwon, Samsung Medical Center:

Primary Outcome Measures:
  • Target vessel failure (TVF) [ Time Frame: 12 months ]
    composite of cardiac death, myocardial infarction, target vessel revascularization


Secondary Outcome Measures:
  • Cardiac death [ Time Frame: 12 months ]
    All deaths were considered cardiac unless a definite non-cardiac cause could be established.

  • Myocardial infarction (MI) [ Time Frame: 12 months ]
    MI was defined as elevated cardiac enzymes (troponin or MB fraction of creatine kinase, CK-MB) more than the upper limit of the normal value with ischemic symptoms or electrocardiography findings indicative of ischemia that was not related to the index procedure.

  • Target vessel revascularization (TVR) [ Time Frame: 12 months ]
    TVR was repeat revascularization of the target vessel by PCI or bypass graft surgery.

  • Target lesion revascularization (TLR) [ Time Frame: 12 months ]
    TLR was defined as repeat PCI of the lesion within 5 mm of stent deployment or bypass graft surgery of the target vessel.

  • Stent thrombosis [ Time Frame: 12 months ]
    Stent thrombosis was assessed based on the definitions of the Academic Research Consortium as definite, probable, or possible stent thrombosis.

  • Periprocedural enzyme elevation [ Time Frame: during the hospitalization ]
    Periprocedural enzyme elevation was defined as a rise in CK-MB ≥3 times the upper normal limit after the index procedure.

  • the incidence of binary angiographic restenosis in the main branch and side branch [ Time Frame: 9 months ]
    as measured by 9-month quantitative coronary analysis


Enrollment: 258
Study Start Date: November 2007
Study Completion Date: February 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Conservative strategy Procedure: Conservative strategy
  • Main vessel stenting was performed.
  • Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow <3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) >75% in LM subgroup.
  • Side branch stenting was performed if TIMI flow <3 in the Side branch after ballooning in non-LM subgroup, and DS >50% or dissection in the Side branch after ballooning in LM subgroup.
Experimental: Aggressive strategy Procedure: Aggressive strategy
  • Main vessel was performed.
  • Side branch ballooning and kissing ballooning were done if DS >75% in the side branch after main vessel stenting in non-LM subgroup, and DS >50% in LM subgroup.
  • Side branch stenting was performed if DS >50% in the side branch after ballooning in non-LM subgroup, and DS >30% or dissection in the side branch after ballooning in LM subgroup.

Detailed Description:
The purpose of this study is to evaluate the relative efficacy and safety of conservative strategy compared to aggressive strategy for side branch stenting in coronary bifurcation lesion.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Parent vessel diameter stenosis > 75%
  • Parent vessel diameter stenosis 50% - 75% with angina and/or objective evidence of ischemia in the non-invasive stress test
  • The reference diameter of both branches more than 2.3 mm by visual estimation

Exclusion Criteria:

  • Cardiogenic shock
  • ST-elevation myocardial infarction within 48 hours of symptom onset
  • Left ventricular dysfunction (echocardiographic left ventricular ejection fraction < 25%)
  • Graft vessels
  • Patients who have to receive clopidogrel due to other conditions
  • Patients who have to receive warfarin, cilostazol or other antiplatelet therapy
  • Hypersensitivity to clopidogrel or aspirin
  • Expectant survival less than 1 year
  • Women who plan to become pregnant
  • Patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, Gastrointestinal or genitourinary bleeding within the prior 3 months)
  • Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00794014


Locations
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Sponsors and Collaborators
Samsung Medical Center
Investigators
Principal Investigator: Hyeon-Cheol Gwon, MD,PhD Samsung Medical Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hyeon-Cheol Gwon, Professor, Samsung Medical Center
ClinicalTrials.gov Identifier: NCT00794014     History of Changes
Other Study ID Numbers: 2007-08-073
First Submitted: November 17, 2008
First Posted: November 19, 2008
Last Update Posted: February 13, 2013
Last Verified: February 2013

Keywords provided by Hyeon-Cheol Gwon, Samsung Medical Center:
Angioplasty, Transluminal, Percutaneous Coronary

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases